Midazolam Accord (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor. By increasing chloride ion influx, it hyperpolarizes neuronal membranes, which suppresses neuronal firing and produces sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.

The dose of Midazolam Accord is individualized by the prescribing clinician based on the patient’s age, weight, clinical condition, route of administration, and response. No fixed regimen can be provided without a qualified medical assessment.

Safety data for midazolam in pregnancy and lactation are limited. It should be used only when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Midazolam has a faster onset of action and a shorter duration of effect compared with diazepam, making it preferable for procedural sedation and acute seizure control. Diazepam, in contrast, is longer‑acting and often used for chronic anxiety or muscle spasm management.

Midazolam Accord should be stored at controlled room temperature, typically below 25 °C, in its original packaging. Protect the product from light, moisture and physical shock. Do not freeze or expose it to extreme temperatures.

The medication is supplied as a sterile solution for intramuscular or intravenous injection. Administration is performed by qualified healthcare personnel, who select the appropriate route, dose and infusion rate according to the clinical indication and patient monitoring requirements.

The most critical risks include severe respiratory depression, paradoxical agitation or aggression, and rare anaphylactic reactions. Continuous monitoring of breathing, oxygen saturation and cardiovascular status is essential, especially when higher doses or concurrent depressant drugs are used.

Midazolam Accord is contraindicated in patients with known hypersensitivity to midazolam or any benzodiazepine, those with severe respiratory insufficiency, and individuals with acute narrow‑angle glaucoma. Caution is also advised for patients with significant hepatic impairment or those taking interacting CNS depressants.